GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (FRA:10VA) » Definitions » Inventories, Finished Goods

Immunic (FRA:10VA) Inventories, Finished Goods : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Immunic Inventories, Finished Goods?


Immunic Inventories, Finished Goods Historical Data

The historical data trend for Immunic's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Inventories, Finished Goods Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunic Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunic Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Immunic Business Description

Industry
Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic Headlines

No Headlines